{"id":"atezolizumab-etoposide-carboplatin-tarlatamab","safety":{"commonSideEffects":[{"rate":"35%","effect":"Fatigue"},{"rate":"30%","effect":"Nausea"},{"rate":"25%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Atezolizumab is a monoclonal antibody that binds to PD-L1, preventing its interaction with PD-1 and thereby enhancing T-cell mediated immune response against cancer cells.","oneSentence":"PD-L1 inhibitor","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:21:40.200Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Urothelial carcinoma"},{"name":"Triple-negative breast cancer"}]},"trialDetails":[{"nctId":"NCT05361395","phase":"PHASE1","title":"First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-08-24","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":184},{"nctId":"NCT06830694","phase":"PHASE2","title":"Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment","status":"RECRUITING","sponsor":"Se-Hoon Lee","startDate":"2025-05-13","conditions":"Small Cell Carcinoma of Lung","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Atezolizumab, Etoposide, Carboplatin, Tarlatamab","genericName":"Atezolizumab, Etoposide, Carboplatin, Tarlatamab","companyName":"Se-Hoon Lee","companyId":"se-hoon-lee","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PD-L1 inhibitor Used for Non-small cell lung cancer, Urothelial carcinoma, Triple-negative breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}